Haitham Hreibe, MD
Clinical Cardiac Electrophysiology · Augusta, GANPI 1275755928
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Abiomed at 28.9% of the total. 2025 is the largest year on record at $13,649, 8.5 times the $1,611 reported in 2019.
Across 358 payments — averaging $95.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$10K
- Impulse Dynamics (USA) Inc.$9K
- Biosense Webster, Inc.$5K
- Medtronic$4K
- Cvrx, Inc.$1K
- Abbott$1K
- plus $3K from 18 others
Across 28 payments — averaging $3910.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$57K
- Janssen Research & Development, LLC$53K
What the payments were for
- Consulting fees$9,38028%
- Speaking & faculty fees$7,80023%
- Travel & lodging$3,0209%
- Food & beverage$13,81841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 19 | $9,841 |
| Impulse Dynamics (USA) Inc. | 15 | $8,970 |
| Biosense Webster, Inc. | 61 | $5,467 |
| Medtronic(2 entities) | 137 | $4,163 |
| Cvrx, Inc. | 22 | $1,331 |
| Abbott | 17 | $1,113 |
| Boston Scientific | 33 | $1,108 |
| Janssen Research & Development, LLC | 8 | $665 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $378 |
| Philips North America LLC | 5 | $132 |
| Stryker | 1 | $126 |
| Cardiva Medical, Inc. | 2 | $122 |
| Inari Medical, Inc. | 1 | $99 |
| Johnson & Johnson | 6 | $93 |
| W. L. Gore & Associates, Inc. | 1 | $67 |
| Novartis | 3 | $63 |
| Irhythm Technologies, Inc. | 2 | $48 |
| Pfizer | 2 | $46 |
| Vital Connect, Inc | 2 | $43 |
| Biotronik Inc. | 1 | $40 |
| Edwards Lifesciences | 1 | $30 |
| AstraZeneca | 2 | $30 |
| Recor Medical Inc | 1 | $25 |
| Angiodynamics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$9,087
- Barostim Neo System$869
- OPTIMIZER$856
- Carto 3$833
- ENSITE$361
- LINQ II$247
- Micra$239
- AMPLATZER Occluders$179
- PulseSelect$173
- AFFERA MAPPING SYSTEM$164
- AVEIR$156
- SelectSecure$141
- AZURE XT DR MRI SURESCAN$131
- RESONATE EL ICD VR$130
- FlowTriever$126
- NA$109
- Arctic Front$108
- COBALT DR MRI SURESCAN$106
- Carto 3 System$102
How this compares
$34,018 in reported general payments places this provider in the 65th percentile of 93 clinical cardiac electrophysiology providers in Georgia.
See all clinical cardiac electrophysiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $83,880 |
| XareltoRivaroxaban | 17 | $10,022 |
| Flecainide Acetate | 45 | $1,547 |
| Amiodarone Hcl | 54 | $950 |
| Metoprolol Succinate | 19 | $223 |
| Metoprolol Tartrate | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $46 | $83,88074 claims |
| Johnson & JohnsonXarelto | $93 | $10,02217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 93 clinical cardiac electrophysiology providers in Georgia.
Other clinical cardiac electrophysiology in Augusta
- William WhiteAugusta$51K
- Joseph LightseyAugusta$45K
- Rajan GaneshAugusta$36K
- Adam BermanAugusta$16K
- Daniel SohinkiAugusta$14K
- David ClarkAugusta$13K
- David DelurgioAtlanta$695K
- Thomas DeeringAtlanta$237K
- David NewtonSavannah$225K
- Michael LloydAtlanta$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.